Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 4/20 | 0.51 |
| ▸ | CCR2 | P41597 | 7/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 3/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3145416 | 0.93 | DRD4 (0.52) | DRD4CCR2SLC6A4SMN1; SMN2DRD3 | |
| SCHEMBL3149584 | 0.92 | CCR2 (0.50) | DRD4CCR2SMN1; SMN2DRD3GAA | |
| SCHEMBL3154547 | 0.90 | DRD4 (0.54) | DRD4CCR2SMN1; SMN2DRD3DRD2 | |
| SCHEMBL3149365 | 0.89 | CCR2 (0.59) | DRD4CCR2SLC6A4SMN1; SMN2GAA | |
| SCHEMBL3145283 | 0.89 | CCR2 (0.49) | CCR2HTT | |
| SCHEMBL3154017 | 0.89 | HTR1A (0.52) | DRD4CCR2SMN1; SMN2DRD3DRD2 | |
| SCHEMBL3139293 | 0.86 | CCR2 (0.51) | CCR2SMN1; SMN2GAA | |
| SCHEMBL3138029 | 0.85 | CCR2 (0.53) | CCR2DRD3DRD2 | |
| SCHEMBL15016167 | 0.84 | CCR2 (0.54) | DRD4CCR2SLC6A4 | |
| SCHEMBL3153343 | 0.84 | DRD2 (0.54) | DRD4DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | DRD4 820/4885CCR2 417/4885SLC6A4 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.